R
Rolf P. Mueller
Researcher at University of Cologne
Publications - 15
Citations - 1567
Rolf P. Mueller is an academic researcher from University of Cologne. The author has contributed to research in topics: Esophageal cancer & ABVD. The author has an hindex of 13, co-authored 15 publications receiving 1453 citations.
Papers
More filters
Journal ArticleDOI
A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results
Riccardo Soffietti,Martin Kocher,Ufuk Abacioglu,Salvador Villà,François Fauchon,Brigitta G. Baumert,L. Fariselli,Tzahala Tzuk-Shina,Rolf-Dieter Kortmann,Christian Carrie,Mohamed Ben Hassel,Mauri Kouri,Egils Valeinis,Dirk van den Berge,Rolf P. Mueller,Gloria Tridello,Laurence Collette,Andrew Bottomley +17 more
TL;DR: This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL, even if these effects are transitory.
Journal ArticleDOI
Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification
Paul M. Schneider,Stephan Baldus,Ralf Metzger,Martin Kocher,Rudolf Bongartz,Elfriede Bollschweiler,Hartmut Schaefer,Juergen Thiele,Hans Peter Dienes,Rolf P. Mueller,Arnulf H. Hoelscher +10 more
TL;DR: Histomorphologic tumor regression and lymph node status (ypN) were significant prognostic parameters for patients with complete resections (R0) following neoadjuvant radiochemotherapy for esophageal cancer.
Journal ArticleDOI
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Bastian von Tresckow,Annette Plütschow,Michael Fuchs,Beate Klimm,Jana Markova,Andreas Lohri,Zdenek Kral,Richard Greil,Max S. Topp,Julia Meissner,Josée M. Zijlstra,Martin Soekler,Harald Stein,Hans Theodor Eich,Rolf P. Mueller,Volker Diehl,Peter Borchmann,Andreas Engert +17 more
TL;DR: Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
Journal ArticleDOI
High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer
Ute Warnecke-Eberz,Ralf Metzger,F. Miyazono,Stephan Baldus,Susanne Neiss,Jan Brabender,Hartmut Schaefer,Walter Doerfler,Elfriede Bollschweiler,Hans Peter Dienes,Rolf P. Mueller,Peter V. Danenberg,Arnulf H. Hoelscher,Paul M. Schneider +13 more
TL;DR: Relative expression levels of ERCC1 mRNA determined by quantitative real-time reverse transcriptase-PCR appear highly specific to predict minor response to neoadjuvant radiochemotherapy protocol in patients with locally advanced esophageal cancer and could be applied to prevent expensive, noneffective, and potentially harmful therapies in a substantial number of patients.
Journal ArticleDOI
High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer
Huan Xi,Stephan Baldus,Ute Warnecke-Eberz,Jan Brabender,Susanne Neiss,Ralf Metzger,Frederike C. Ling,Hans Peter Dienes,Elfriede Bollschweiler,Stefan Paul Moenig,Rolf P. Mueller,Arnulf H. Hoelscher,Paul M. Schneider +12 more
TL;DR: High COX-2 protein expression following neoadjuvant radiochemotherapy in resection specimens is significantly associated with minor histopathologic response to neoadedjuvant therapy and very poor prognosis.